Skin problems can often be ignored as simple rashes or breakouts. But sometimes an itchy patch or the random blisters may ...

Explore the latest advancements in rheumatology biosimilars, including FDA approvals, patient switching trends, and ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

The dermatology market in the U.S. is at a pivotal moment of transformation, with spending poised to climb from $40.55 billion in 2023 to $70 billion by 2030. This unprecedented growth mirrors past ...

U.K. adults with psoriasis may be compromising their health and risking exacerbating their skin condition by seeking ...

Arcutis is financially strong, with over 30 months of cash runway. The atopic dermatitis market is large and shifting away ...

JACK MAYE didn’t want to tell anybody. In his freshman year, when he took off his Bedford High School football helmet and flakes fell out, Maye’s teammates would tell him that he had some bad dandruff ...

JACK MAYE didn’t want to tell anybody. In his freshman year, when he took off his Bedford High School football helmet and flakes fell out, Maye’s teammates would tell him that he had some bad dandruff ...

The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years with plaque psoriasis or ...

Compared with adalimumab, several biologic medications had superior safety profiles for the treatment of moderate to severe psoriasis.

Icotrokinra was safe and effective for improving skin clearance among patients with at least moderate psoriasis in ...

However, this new study, led by researcher Hye Sun Gwak, reviewed data from 13 different studies and found that some of these ...